Plenary Speaker

Ron Wange, PhD

Principal Consultant @ Aclairo Pharmaceutical Development Group

Title TBA

Jenna Moccia, PhD

Director, Product Management,Epithelial and Pluripotent Stem Cell Biology @ STEMCELL Technologies

Intestinal and Hepatic Organoid Systems: In Vitro Models of Drug Toxicity

Sophie Tourdot, PhD

Immunogenicity Sciences Lead @ Pfizer

Hapten/ADA response and state of ADA in tox - Title TBA

Russell Naven, PhD

Head, Predictive Safety Data Exploration @ Novartis

BAPTG in AI prediction of Tox using computational methods - title TBA

Matt Wagoner, PhD

Global Head of Investigative Toxicology @ Takeda Pharmaceuticals

Predicting DILI with AI Transcriptomics - Title TBA

Radhakrishna Sura, PhD, DABT, DACVP

Senior Director, Nonclinical Safety and Pathobiology @ Gilead Sciences, Inc.

New Approach Methodologies (NAMs): Role of Nonclinical Scientists

Zhechu Peng, PhD, DABT

Director Project Toxicologist Immune Safety @ AstraZeneca

in vitro only toxicology package for a T-cell engagers across 2 indications - title TBA

Giel Hendriks, PhD

CEO @ Toxys Inc.

In Vitro Developmental Toxicity Testing of PROteolysis-Targeting Chimeras (PROTACs)

Kim Rockley

 @ AconiX

Benefits of Early In Vitro Screening for Seizure Liability in Problem Solving and Decision Making

Kaushik Datta, PhD, DABT

Distinguished Scientist and Therapeutic Area Lead @ Merck

IQ Survey - Strategies to Reduce NHP Use in the Nonclinical Development of Oncology Therapeutics 

Petra Lutterbuese, PhD, DABT

Principal Scientist @ Amgen (Munich)

Alternative Approaches During T Cell Engager Development: Regulatory Interactions, Scientific Rigor, and Reduced NHP Usage

Sheroy Minocherhomji, PhD, ERT, FRSB

Senior Director, Nonclinical Safety and Toxicology @ Eli Lilly and Company

Nonclinical Developmental Considerations of RNA-based Complex Biologics

Rhiannon Hardwick, PhD, DABT

Scientific Director, Discovery Toxicology @ Bristol Myers Squibb 

tox strategies /in vitro species selection and off-target profiling and how that leads into in vivo PD profiling and off-target assessment - title TBA

Wei Wang, PhD, DABT

Director @ Eli Lilly

tox profiles of GLP-1 agonists and oral peptides - Title TBA

John Vahle, PhD, DVM

Senior Research Fellow @ Eli Lilly

evolution of safety strategy over past decade - title TBA

Marie Lemper, PharmD, PhD, DABT, ERT, MSc

Head of US Toxicology @ UCB

Title TBA

Qi Sun, ScD, M.D.

Associate Professor in the Departments of Nutrition & Epidemiology, Harvard T.H. Chan School of Public Health 

Body Weight Modulation: Contributors and Cardiometabolic Health Consequences 

Matthew Lalonde, PhD, DABT

Director Toxicology @ Kymera Therapeutics

In vitro/in vivo DART with KT-474- Talk title TBA

Ryan Polli, PhD

Associate Director, PK Sciences @ Novartis Institutes for Biomedical Research

T cell engagers for non-oncology  indications: bench to bedside considerations for dose and safety

Nirav Patel, PhD

Global Head of Immune Oncology Safety Science @ AstraZeneca

Integrating T‑Cell Engagers: Evolution, Preclinical safety packages in Oncology

  Kavita Raman, PhD

Sr. Principal Scientist II (Assoc. Director) @ Johnson & Johnson Innovative Medicine

Talk title TBA

Rebecca Kohnken, DVM, PhD, DACVP

Senior Principal Pathologist @ AbbVie

Use of NAMs to Support Early Safety Assessment in Drug Development 

 Spotlight Talk

Runxi Shen, PhD

Postdoctoral Associate, Broad Institute of MIT and Harvard

Talk title TBA

Onyi Irrechukwu, PhD, DABT

Associate Scientific Director @ Johnson & Johnson Innovation Medicine

ADC/Cytotoxic payload

 Lise Loberg, PhD, DABT

Senior Research Fellow @ AbbVie

Talk title TBA

Tracey Papenfuss, PhD

Senior Pathologist, Immune Service Lead @ StageBio

Talk title TBD